Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Pieris Pharmaceuticals and AstraZeneca Present Multiple Ascending Dose Phase 1b Data for Inhaled IL4-Rα Antagonist AZD1402/PRS-060 at the 2019 European Respiratory Society International Congress
BiotechnologyCompany Update

Pieris Pharmaceuticals and AstraZeneca Present Multiple Ascending Dose Phase 1b Data for Inhaled IL4-Rα Antagonist AZD1402/PRS-060 at the 2019 European Respiratory Society International Congress

September 26, 2019 9:35 AM

BOSTON, MA / ACCESSWIRE / September 26, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the presentation on October 1, 2019, of interim data from its placebo-controlled multiple ascending dose phase 1b study for AZD1402/PRS-060, an inhaled IL4-Rα...

Read more
Hancock Jaffe to Host Virtual Roadshow Webinar on Thursday, October 3, 2019 at 4:30 p.m. Eastern Time
BiotechnologyCompany Update

Hancock Jaffe to Host Virtual Roadshow Webinar on Thursday, October 3, 2019 at 4:30 p.m. Eastern Time

September 26, 2019 8:31 AM

IRVINE, CA / ACCESSWIRE / September 26, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, will host a virtual roadshow webinar on October 3, 2019 at 4:30 p.m. Eastern time. Robert Berman, Chief Executive Officer and Dr. Marc H. Glickman, Chief Medical Officer, will present an overview of the company's product pipeline, review of interim data and a...

Read more
Cofactor Genomics Expands Leadership Team and Opens New Boston Predictive Immune Modeling Center
BiotechnologyCompany UpdateManagement Changes

Cofactor Genomics Expands Leadership Team and Opens New Boston Predictive Immune Modeling Center

September 26, 2019 7:00 AM

BOSTON, MA / ACCESSWIRE / September 26, 2019 / Today Cofactor Genomics announced that it has expanded the leadership team with the promotion of Natalie LaFranzo, PhD to Vice President of Market Development. Dr. LaFranzo's amplified leadership role includes clinical collaboration management, corporate partnerships, and strategic marketing. Dr. LaFranzo has been with Cofactor most recently for three years, with previous roles in product management...

Read more
ReShape Lifesciences Enters into Early Warrant Exercise Transaction and Receives an Additional $7.65 Million in Proceeds
BiotechnologyCompany Update

ReShape Lifesciences Enters into Early Warrant Exercise Transaction and Receives an Additional $7.65 Million in Proceeds

September 23, 2019 4:55 PM

SAN CLEMENTE, CA / ACCESSWIRE / September 23, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today entered into an early warrant exercise transaction with the holders of 400,000,000 Series B Warrants issued in ReShape's June 2019 private placement pursuant to a warrant exercise agreement. The early exercise of the warrants resulted in approximately $7.65...

Read more
DECN Retains Counsel To File For Two Patents Covering GenUltimate TBG Test Strip And System, Consents To The Publication A White Paper By A Biotech Industry Luminary
BiotechnologyCompany Update

DECN Retains Counsel To File For Two Patents Covering GenUltimate TBG Test Strip And System, Consents To The Publication A White Paper By A Biotech Industry Luminary

September 19, 2019 8:55 AM

3RD PARTY TESTING AND ANALYSIS OF COMPANY'S GENULTIMATE TBG REVEAL NEVER BEFORE SEEN PRECISION AND ACCURACY AT LEVELS 60% BETTER THAN FDA AND ISO PUBLISHED STANDARDS LOS ANGELES, CA / ACCESSWIRE / September 19, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive...

Read more
American CryoStem Announces:  FDA Accepted its Investigational New Drug Application for Post Concussion Syndrome
BiotechnologyCompany Update

American CryoStem Announces: FDA Accepted its Investigational New Drug Application for Post Concussion Syndrome

September 18, 2019 6:00 AM

ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed via Intravenous Infusion for the Treatment of Post Concussion Syndrome (PCS) in Retired Military and Athletes EATONTOWN, NJ / ACCESSWIRE / September 18, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized...

Read more
Hancock Jaffe Appoints Global Healthcare Executive Matthew Jenusaitis and Financial and Medical Reimbursement Expert Robert Gray to its Board of Directors
BiotechnologyCompany Update

Hancock Jaffe Appoints Global Healthcare Executive Matthew Jenusaitis and Financial and Medical Reimbursement Expert Robert Gray to its Board of Directors

September 16, 2019 8:31 AM

Experienced Medical Device and Reimbursement Executives Added to Board Ahead of Key Product Milestones and Pre-FDA Meetings IRVINE, CA / ACCESSWIRE / September 16, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, has appointed global healthcare executive Mr. Matthew Jenusaitis and reimbursement and financial expert Mr. Robert Gray to its board of...

Read more
DECN Launches Premier Versions Of Its Successful Genultimate Test Strip, Completes Media Commercial Set To Debut In National Media Markets
BiotechnologyProduct Announcements

DECN Launches Premier Versions Of Its Successful Genultimate Test Strip, Completes Media Commercial Set To Debut In National Media Markets

September 11, 2019 8:55 AM

LOS ANGELES, CA / ACCESSWIRE / September 11, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the GenSure! ("Feather") diabetes test strip for International...

Read more
American CryoStem Engages BioSolutions Clinical Research Center, LLC. and Principal Investigator for Chronic Concussive Syndrome IND
BiotechnologyCompany Update

American CryoStem Engages BioSolutions Clinical Research Center, LLC. and Principal Investigator for Chronic Concussive Syndrome IND

September 11, 2019 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / September 11, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has contracted with BioSolutions Clinical Research Center, LLC. (“BioSolutions”) to conduct a clinical study (“Study”) of ATCELL™...

Read more
Leveraging GeoVax's Vaccine Expertise To Take On Cancer
BiotechnologyInvestor Relations

Leveraging GeoVax's Vaccine Expertise To Take On Cancer

September 9, 2019 8:00 AM

ATLANTA, GA / ACCESSWIRE / September 9, 2019 / GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing human immunotherapies and vaccines has historically been associated with the development of vaccines against infectious diseases. The company is now leveraging the knowledge and expertise it has validated in infectious diseases and expanding the applicability of MVA-VLP into immuno-oncology (IO) with highly promising results. Click...

Read more
Edesa Biotech Receives Approval to Initiate Clinical Study in Patients with Hemorrhoids
BiotechnologyCompany Update

Edesa Biotech Receives Approval to Initiate Clinical Study in Patients with Hemorrhoids

September 5, 2019 7:30 AM

TORONTO, ON / ACCESSWIRE / September 5, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from Health Canada to begin a clinical study of its investigational drug, EB02, which the company is developing as a potential treatment for patients with grade I-III internal hemorrhoids. Health Canada reviewed Edesa’s clinical trial application and approved it by issuing a "no objection letter," a...

Read more
Dyadic to Present at Janney Healthcare Conference
BiotechnologyConferences

Dyadic to Present at Janney Healthcare Conference

September 4, 2019 8:00 AM

JUPITER, FL / ACCESSWIRE / September 4, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive...

Read more
Interface Biologics Announces Sale of Surface Modification Business to Evonik
BiotechnologyCompany Update

Interface Biologics Announces Sale of Surface Modification Business to Evonik

September 3, 2019 9:00 AM

TORONTO, CANADA / ACCESSWIRE / September 3, 2019 / Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the sale of its surface modification business to Evonik (EVR:ETK), a German based specialty chemical company with revenues in excess of €13 billion in 2018. The Health Care business line of Evonik, a leading...

Read more
Pieris Pharmaceuticals Announces Changes to Senior Management Team
BiotechnologyManagement Changes

Pieris Pharmaceuticals Announces Changes to Senior Management Team

September 3, 2019 7:30 AM

BOSTON, MA / ACCESSWIRE / September 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the appointment of Hitto Kaufmann, Ph.D. as Senior Vice President and Chief Scientific Officer and the departure of Allan Reine, M.D., Senior Vice President and...

Read more
Hancock Jaffe Medical Advisory Board Member Dr. Steven Elias Presents at International Union of Phlebology Conference in Krakow, Poland
BiotechnologyCompany UpdateConferences

Hancock Jaffe Medical Advisory Board Member Dr. Steven Elias Presents at International Union of Phlebology Conference in Krakow, Poland

August 29, 2019 8:31 AM

Presentation Featured VenoValve as Potential Treatment of Chronic Venous Disease IRVINE, CA / ACCESSWIRE / August 29, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on August 25, 2019, Dr. Steven Elias, a member Hancock Jaffe's Medical Advisory Board, made a presentation which featured Hancock Jaffe's VenoValve, at the International...

Read more
Edesa Biotech to Present at H. C. Wainwright Global Investment Conference
BiotechnologyConferences

Edesa Biotech to Present at H. C. Wainwright Global Investment Conference

August 29, 2019 8:30 AM

TORONTO, ON / ACCESSWIRE / August 29, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, will present at the H. C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019 in New York City. Edesa Presentation Details Date: Monday, September 9, 2019 Time: 2:35 pm Eastern Time Location: Lotte New York Palace Hotel Edesa...

Read more
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
BiotechnologyCompany Update

Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

August 29, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that members of the management team will participate in the following upcoming investor conferences: Citi 14th Annual Biotech Conference Wednesday, September 4,...

Read more
EBD Group: Europe's largest annual life sciences partnering conference convenes in Hamburg for its 25th anniversary
BiotechnologyConferencesConference Call

EBD Group: Europe's largest annual life sciences partnering conference convenes in Hamburg for its 25th anniversary

August 29, 2019 3:10 AM

Europe's largest annual life sciences partnering conference convenes in Hamburg for its 25th anniversary CARLSBAD, CA & HAMBURG, GERMANY / ACCESSWIRE / August 29, 2019 / The 25th annual BIO-Europe(R) global life science partnering event will be held November 11-13, 2019, in Hamburg, Germany, supported by regional hosts Life Science Nord, the City of Hamburg, and the State of Schleswig-Holstein. The event is expected to bring together 4,400...

Read more
Hancock Jaffe to Present at H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019
BiotechnologyConferences

Hancock Jaffe to Present at H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019

August 27, 2019 8:31 AM

IRVINE, CA / ACCESSWIRE / August 27, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) (NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, has been invited to present at the H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019 in New York City. H.C. Wainwright 21st Annual Global Investment Conference is being held September 8-10, 2019 at the Lotte New York Palace Hotel in New...

Read more
Molecular Partners Reports Key Financials for H1 19 and Corporate Highlights: EMA has Validated the Marketing Authorization Application for Abicipar; Focus of MP0250 on Multiple Myeloma with Expected Initiation of Ph2 Imid Trial in Q4 19; MP0310 Ph1 Start on Track for H2 19
BiotechnologyEarnings

Molecular Partners Reports Key Financials for H1 19 and Corporate Highlights: EMA has Validated the Marketing Authorization Application for Abicipar; Focus of MP0250 on Multiple Myeloma with Expected Initiation of Ph2 Imid Trial in Q4 19; MP0310 Ph1 Start on Track for H2 19

August 27, 2019 1:00 AM

Research & Development: MP0250 (VEGF x HGF) in MM: PI Trial (in combination with Velcade®) - Encouraging responses observed in first patient cohorts triggered decision for further investment; IMiD Trial (in combination with Pomalyst®) - Start of phase 2 trial expected in Q4 19, having received FDA approval MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR-mut NSCLC) in combination with Tagrisso®: Following lift of partial...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?